Menu Search
Equities

Novo Nordisk A/S

NOVO B:CPH

Novo Nordisk A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)633.60
  • Today's Change-5.40 / -0.85%
  • Shares traded1.91m
  • 1 Year change+44.25%
  • Beta0.8556
Data delayed at least 15 minutes, as of Jan 18 2022 15:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Jan-21
  • 14-Oct-21
  • 18-Nov-21
  • 16-Dec-21
  • 17-Jan-22
Select bar for recommendation details.
Recommendations17-Jan-22
Buy2
Outperform4
Hold18
Underperform6
Sell1

Share price forecast

The 28 analysts offering 12 month price targets for Novo Nordisk A/S have a median target of 702.50, with a high estimate of 850.00 and a low estimate of 390.00. The median estimate represents a 9.94% increase from the last price of 639.00.
High33.0%850.00
Med9.9%702.50
Low-39.0%390.00

Dividends

In 2020, Novo Nordisk A/S reported a dividend of 9.10 DKK, which represents a 8.98% increase over last year. The 21 analysts covering the company expect dividends of 10.29 DKK for the upcoming fiscal year, an increase of 13.12%.
Div growth (TTM)8.98%
More ▼

Earnings history & estimates

On Nov 03, 2021, Novo Nordisk A/S reported 3rd quarter 2021 earnings of 5.27 per share. This result exceeded the 5.00 consensus of the 11 analysts covering the company and exceeded last year's 3rd quarter results by 19.23%.
The next earnings announcement is expected on Feb 02, 2022.
Average growth rate+5.83%
Novo Nordisk A/S reported annual 2020 earnings of 18.01 per share on Feb 03, 2021.
Average growth rate+4.79%
More ▼

Revenue history & estimates

Novo Nordisk A/S had 3rd quarter 2021 revenues of 35.62bn. This bettered the 34.54bn consensus of the 11 analysts covering the company. This was 5.16% above the prior year's 3rd quarter results.
Average growth rate+3.66%
Novo Nordisk A/S had revenues for the full year 2020 of 126.95bn. This was 4.04% above the prior year's results.
Average growth rate+3.30%
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.